Hacer clic aquí para regresar a la portada

english    français
../../../175pxls.gif (78 bytes)
   EN ESTA PÁGINA  Access   Financing   Pricing   Experience   Market segmentation   Purchasers   Perspectives
portada > temas comerciales >  adpic >  noticias  >  taller sobre los medicamentos > exposiciones

175pxls.gif (835 bytes)
Pulsar aquí para regresar a "temas comerciales"

 ADPIC: TALLER DE LA OMS Y LA OMC SOBRE LA FINANCIACIÓN Y LA FIJACIÓN DE LOS PRECIOS DE LOS MEDICAMENTOS (HØSBJØR 2001)
Exposiciones
(solamente en inglès)

Descargar los textos de las transparencias PowerPoint presentadas en el Taller. Estos ficheros contienen las exposiciones que los oradores nos han enviado y nos han autorizado a distribuir. Aquí se incluyen casi todas las exposiciones, pero seguimos comprobando si queda alguna por distribuir. Las incluiremos aquí cuando nos sean facilitadas.

> Ver también el informe final

175pxls.gif (835 bytes)

> Guía para descargar ficheros

 
 
Nota:

El taller, que se celebrará los días 8 a 11 de abril de 2001 en Høsbjør, Noruega, reunirá a 80 expertos, aproximadamente de países industrializados y países en desarrollo. Organizado conjuntamente por la Organización Mundial de la Salud, la Organización Mundial del Comercio, el Ministro de Relaciones Exteriores de Noruega y el Global Health Council, organización estadounidense de amplia base en la esfera de la atención sanitaria.

> Más información sobre les ADPIC

Opening Session  volver al principio

  • Sigrun Møgedal, State Secretary of International Development, Norway: Opening statement (MS Word, 2 pages, 27.5KB)(pdf, 14KB)
  • Dr Gro Harlem Brundtland, Director-General, WHO — Opening remarks (browse)
  • Adrian Otten, WTO Secretariat — Introductory remarks (browse)
  • Nils Daulaire, President, Global Health Council: Opening statement (MS Word, 2 pages, 27.5KB)(pdf, 7KB)
  • Peter Piot, Executive Director, UNAIDS: Opening statement (MS Word, 5 pages, 119KB)(pdf,  51KB)

 
Session I — Access to Essential Drugs in Low Income Countries: Key Issues  volver al principio

This session examined the range of obstacles to adequate access to essential drugs in developing countries, including issues of financing, pricing, supply, selection and distribution. It, amongst other things, sought to examine the respective importance of the various factors, including the significance of patent protection.

 
Session II — The Role of Financing in Ensuring Access to Essential Drugs  volver al principio

This session considered the financing needs for ensuring adequate access to essential drugs in developing countries, even in an environment of differential pricing, and how such financing can be mobilized.

 
Session III — Differential Pricing: Concepts and Issues  back to top

This session sought to identify key issues that need to be explored in regard to differential pricing of essential drugs, whether patented or generic, and to examine what economic analysis can tell us about whether, and under what conditions, differential pricing can be a win-win policy and to what extent there could be losers.

Economic analysis

Conceptual issues

 
Session IV — Current Experience with Differential Pricing  back to top

The purpose of this session was to examine to what extent differential pricing occurs already and what can be learnt from this experience, for example in regard to techniques for ensuring market segmentation and managing reactions in industrial countries.

 
Session V — Market Segmentation: Techniques, Actors and Incentives  back to top

This session sought to examine the different ways in which the segmentation of markets necessary for differential pricing can be made effective, taking into account the need to ensure consistency with WTO and other international trade rules. Also considered were the extent to which competition law puts constraints on the use of market segmentation techniques.

Marketing strategies by manufacturers and contractual approaches

Governmental measures

The use of intellectual property rights

Competition policy considerations

 
Session VI — Purchaser Perspectives and Incentives for Differential Pricing

This session considered the perspectives of purchasers in high and low income markets and consider their influence on the price of essential drugs. It asked whether differential pricing for low income countries will put downward pressure on prices in industrialized countries even with market segmentation. It considered existing and potential fiscal and other incentives for companies to implement differential pricing.

 
Session VII — Perspectives on Financing and Differential Pricing  back to top

This session provided an opportunity for a range of views on the issues under discussion in the Workshop to be provided from different perspectives, and for general discussion of these matters. Among the questions considered were how to deal with problems of the political acceptability in developed country markets of lower prices in developing countries.

 
Closing remarks


para contactarnos : Organización Mundial del Comercio, rue de Lausanne 154, CH-1211 Ginebra 21, Suiza